{"ticker": {"uuid": "06cbd92e-bfa2-4121-91be-f5bd9fb2ef43", "symbol": "PMVP", "name": "Pmv Pharmaceuticals\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ArrowMark Colorado Holdings (PMVP) holds 3.67% stake in PMV Pharmaceuticals", "summary": "ArrowMark Colorado Holdings, LLC has reported a 3.67% beneficial ownership stake in PMV Pharmaceuticals, Inc., totaling 1,959,579 shares of common stock as of June 30, 2026. This filing, an amendment to Schedule 13G, indicates ArrowMark holds sole voting and dispositive power ove", "url": "https://www.stocktitan.net/sec-filings/PMVP/schedule-13g-a-pmv-pharmaceuticals-inc-amended-passive-investment-dis-ceb6fa3c125f.html", "source_name": "Stock Titan", "published_at": "2026-07-10T15:41:00", "published_display": "10 Jul 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Coverage Assumed by Ladenburg Thalmann at Buy", "summary": "Ladenburg Thalmann has initiated coverage on PMV Pharmaceuticals (NASDAQ:PMVP) stock with a \"Buy\" rating. The firm has set a new price target of $17.00 for the biopharmaceutical company, indicating confidence in its future performance.", "url": "https://www.moomoo.com/news/post/72660637/pmv-pharmaceuticals-coverage-assumed-by-ladenburg-thalmann-at-buy", "source_name": "Moomoo", "published_at": "2026-07-09T08:40:55", "published_display": "09 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Price Target Announced at $3.00/Share by Ladenburg Thalmann", "summary": "Ladenburg Thalmann has set a price target of $3.00 per share for PMV Pharmaceuticals (NASDAQ:PMVP). This announcement reflects an analyst's valuation of the company's stock, providing investors with a benchmark for potential future performance.", "url": "https://www.moomoo.com/news/post/72660635/pmv-pharmaceuticals-price-target-announced-at-3-00-share-by", "source_name": "Moomoo", "published_at": "2026-07-08T20:39:21", "published_display": "08 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals outlines its cancer drug pipeline as shares trade quietly", "summary": "PMV Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on precision oncology by targeting the p53 pathway in cancer. The company's pipeline revolves around developing therapies that modulate this key tumor suppressor mechanism, positioning it within the precisio", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pmv-pharmaceuticals-outlines-its-cancer-drug-pipeline-as-shares-trade/69715181", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:10:45", "published_display": "07 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals holds the focus as investors await the next catalyst.", "summary": "PMV Pharmaceuticals, an oncology company focused on p53 mutations, is attracting investor attention, with its stock performance heavily reliant on its clinical pipeline, financing, and trial readouts rather than a single event. The company's lead candidate, PMV-02, targets specif", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pmv-pharmaceuticals-holds-the-focus-as-investors-await-the-next-catalyst/69682268", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T18:40:24", "published_display": "03 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article provides the \"Price to earnings forward\" value for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP). It's a quick data point for the company's financial overview, indicating a specific period, value, and change metrics. The article is hosted on TradingView, a financial chart", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:10:40", "published_display": "28 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article displays the forward price-to-sales ratio for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP). It is a financial data point presented by TradingView, indicating the company's valuation based on its future sales. The page also lists associated market data providers and copyri", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:24", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PMVP)", "summary": "This article provides an overview of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) stock performance, financial actuals, and analyst estimates. It details the current stock price, market capitalization, earnings, and revenue, alongside historical highs and lows. The piece also includes", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T03:10:08", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article focuses on the \"Price to book forward\" financial metric for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP). It appears to be a stub or a section within a larger financial data platform, providing a snapshot of this specific financial ratio without additional commentary or ", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:47", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article provides the enterprise value to EBITDA forward for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP). It specifies that the market is currently closed with no trades, and the content is primarily a data point presented within the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T07:41:04", "published_display": "25 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPOWprcm5KLVoyMFdmWlRsRmdpVG1aX1JOTUEyVG9xekVVSVJhNTZ5ME1UUVB6ZnlSTzZSRmZ3SU1DU2syRlhPQXlRVG1xRnZaR0RqZ2pYd3hBT29PRXN0bGk1M1BuSVBEZ0IzZ2VDY1lUakJtQ1RRWkY4a0tKbFJQMFEyakRqVnNFLUF0V1Y4REh4dExxdFYtWnY2TmRBZVJ6YnNtNA?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Institutional Confidence", "summary": "This article provides details on the institutional confidence in PMV Pharmaceuticals Inc (PMVP), as reflected by institutional shareholding data. It lists key institutional shareholders, their shareholdings, and changes in their positions. The data indicates varying levels of act", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T23:39:17", "published_display": "18 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for PMV Pharmaceuticals Inc (PMVP), including EPS and revenue growth estimates. Based on 5 analysts, the stock has a \"Buy\" rating with an average target price of $6.00, representing a significant upside. The article also details recent a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:39", "published_display": "18 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for PMV Pharmaceuticals Inc (PMVP), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these metrics have not yet been disclosed by the company. The article also includes current stock perfo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:39", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of PMV Pharmaceuticals Inc (PMVP), detailing its current stock price, market cap, and a breakdown of various technical indicators and moving averages. The analysis includes a summary of buy and sell signals based on MACD, RSI, KDJ, and o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/technical", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:39", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a detailed financial overview of PMV Pharmaceuticals Inc (PMVP). It highlights that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The article includes current stock pricing, market c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:48", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of PMV Pharmaceuticals Inc (PMVP) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years and shows no historical data for stock splits. The current stock price a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:47", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMVP SEC Filings - Pmv Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Pmv Pharmaceuticals (PMVP) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details recent filings such as an 8-K report from August 2025 and several Form 4 insider transaction disclosures from July 2025, which i", "url": "https://www.stocktitan.net/sec-filings/PMVP/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-14T23:40:49", "published_display": "14 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Stock (US7301281085): Quiet session puts fundamentals and balance sheet in focus", "summary": "PMV Pharmaceuticals (PMVP) is experiencing a quiet trading session, bringing focus to its fundamentals, clinical pipeline, and cash position. As a clinical-stage oncology company, its valuation is currently based on its lead p53-targeted program, discovery platform, and balance s", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pmv-pharmaceuticals-stock-us7301281085-quiet-session-puts-fundamentals/69528818", "source_name": "AD HOC NEWS", "published_at": "2026-06-12T15:39:06", "published_display": "12 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) Q1 2026 Earnings: EPS Beat Driven by Tight Cost Control, Stock Slips on Lack of Revenue - Free Cash Flow Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNZ0xxM3JBb090SlRYRGZldnhkNWpuTjIweUJ0OUxxdUg1bXE5Wm9fVXZ3T1BROUtIdm80dDR5OUtKSWNUVUhSeXhaUTVNdExCREFDRnIxby1mcld1elZ1YWx1S3FEZ0h3aUlnOEUtREx1TkNVQ0pnZVptUmRLcGRYYlp2U1VHcmdhMHprR2hSVzBqQkxXWHVKblVkUFpXNUxkOExsT0VSMzVIbTM0RkxBVkZsbVFmT3VBZW5MekhwalNKLWZ2WEVMQm1sVnFncGhxcXJFTWpDYUZIM21VM1BhVS1rVGF3Zw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "PMV Pharmaceuticals (PMVP) has dropped 26.1% in the past four weeks but may be poised for a trend reversal due to its oversold status, indicated by an RSI of 27.99. Additionally, Wall Street analysts have significantly raised their earnings estimates for the company, and PMVP hol", "url": "https://finance.yahoo.com/markets/stocks/articles/pmv-pharmaceuticals-pmvp-loses-26-133502096.html", "source_name": "Market source", "published_at": "2026-06-10T09:35:00", "published_display": "10 Jun 2026 09:35", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) director receives 42,000 stock options at $1.1900", "summary": "PMV Pharmaceuticals director Arnold J. Levine was granted 42,000 stock options at an exercise price of $1.1900 per share, as reported in a Form 4 SEC filing. These options are set to expire on June 4, 2036, and will vest on the earlier of June 4, 2027, or the company's next annua", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-445e8f3bf3fd.html", "source_name": "Stock Titan", "published_at": "2026-06-06T08:10:56", "published_display": "06 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) director awarded 42,000 stock options at $1.19", "summary": "PMV Pharmaceuticals director Kirsten Flowers was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. These options will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting. This insider transaction in", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-7f57522338d4.html", "source_name": "Stock Titan", "published_at": "2026-06-06T06:10:40", "published_display": "06 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) director gifts 84K stock options to trust", "summary": "PMV Pharmaceuticals director Carol Giltner Gallagher recently reported that she received a stock option grant for 42,000 shares and transferred options covering a total of 84,000 shares as bona fide gifts, primarily to The Gallagher Revocable Trust. These transactions were non-ma", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-63219f14b852.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:40:11", "published_display": "05 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) grants director 42,000 options at $1.19", "summary": "PMV Pharmaceuticals director Laurie Stelzer was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. These options will vest on the earlier of June 4, 2027, or the date of the company's next annual stockholder meeting. This transaction", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-5f492428899e.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:40:11", "published_display": "05 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at PMV Pharmaceuticals (PMVP) granted 42,000 options at $1.19", "summary": "PMV Pharmaceuticals director Charles M. Baum was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. The options will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting. Following this transaction, M", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-a5b14a55b13f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:40:11", "published_display": "05 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results", "summary": "PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) announced the results of its 2026 Annual Meeting of Stockholders held virtually on June 4, 2026. Key outcomes included the election of two Class III Directors, David H. Mack, Ph.D. and Laurie Stelzer, and a non-binding advisory approval of", "url": "https://www.minichart.com.sg/2026/06/05/pmv-pharmaceuticals-inc-files-form-8-k-with-sec-detailing-company-information-and-annual-meeting-results/", "source_name": "Minichart", "published_at": "2026-06-05T14:04:11", "published_display": "05 Jun 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders back PMV Pharmaceuticals (NASDAQ: PMVP) board, pay plans", "summary": "PMV Pharmaceuticals (NASDAQ: PMVP) shareholders at their 2026 annual meeting elected David H. Mack, Ph.D. and Laurie Stelzer as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation for named executive of", "url": "https://www.stocktitan.net/sec-filings/PMVP/8-k-pmv-pharmaceuticals-inc-reports-material-event-0adc52b9e1a2.html", "source_name": "Stock Titan", "published_at": "2026-06-05T12:39:39", "published_display": "05 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity", "summary": "PMV Pharmaceuticals, Inc. (PMVP) shows positive clinical trial activity for rezatapopt in cancer treatment, prompting Oppenheimer to maintain an Outperform rating despite a reduced price target. Although the company has sufficient cash for operations through Q1 2027 for NDA submi", "url": "https://www.insidermonkey.com/blog/why-pmv-pharmaceuticals-inc-pmvp-faces-funding-concerns-despite-positive-trial-activity-1773525/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-02T16:10:50", "published_display": "02 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Popular Penny Stocks on Robinhood to Watch in 2026", "summary": "PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is highlighted as a popular penny stock on Robinhood. Oppenheimer recently reduced its price target on PMVP to $5, maintaining an Outperform rating, recognizing encouraging clinical activity for rezatapopt in cancer treatment. The company ", "url": "https://www.insidermonkey.com/blog/5-popular-penny-stocks-on-robinhood-to-watch-in-2026-1771177/4/", "source_name": "Insider Monkey", "published_at": "2026-05-31T15:09:34", "published_display": "31 May 2026 15:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals, Inc. - Common Stock (Nasdaq:PMVP) Stock Quote", "summary": "This page provides a stock quote and detailed financial information for PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), including its current price, trading volume, and 52-week range. It also features a feed of recent news and performance data for the company, highlighting drug develop", "url": "https://markets.financialcontent.com/stocks/quote?Symbol=537%3A2578286838&Language=Spanish", "source_name": "FinancialContent", "published_at": "2026-05-16T09:39:48", "published_display": "16 May 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article provides details on the number of shareholders for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP). It is a financial data page from TradingView, explicitly stating the company's ticker and market. The content primarily focuses on presenting shareholder data with period, va", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-15T20:40:41", "published_display": "15 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pmv-pharmaceuticals-reports-first-quarter-120000541.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T12:00:00+00:00", "published_display": "12 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PMV Pharmaceuticals Announces Board Chair Transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOR0x5SlhfR3hCcEt5Z1NfTnV3SlpoaG9mMzdCankzMlNZWDc2cExPYkstV0RweXpYWHh1STBGZUlndDlad2dfOThGRkVKeWRRRXRidzNuWTdtMk9sZ1hON1ZJd2l4QnhHNEF6XzRCdDBhXzJDbEtSMmpGdERDQUtqWlh5bDlNYUVTZ2NVQlJzM1Y1RDRmZS1ZQVNscjFFdUpZSVVoSmpVd2hEb0xiekVQVkxTUkpILTAzSlRwS0w3SXBOQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRWMteFZsN3R3dUY4eXpDTThkMlV2YzFwclF2bVRjTEdIbV9EQ013YV9PLWtaS2ZQTWxDbXJ2N2FEanhhZkVHZEIwWGh2dk9YOUt4NGp6OGEzSnN1c2ZLUlV2UUJORVdSaFY4b0VIb2RFNTZJMV9rQmtuNVN1cUZVOHdtdnBPcHNJRWMtelc2MVZfUV9DQWx1NmNWSVlMOGx5ZkNB?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxPY2s0eEdaaE9FMlhpOFFiM0RSd25zVF80Y096RnBXTlZvVU0wbG03Y1dXV3ppZVpjcW1KU3hfUFZGLU1DM3MxQ2htSFdPZy01SGpBdUxDSF9ka09tRktLdVVuNUxyT0F3c3B5MnBOQjlnbnp0M0dEd29zNi1NSTUxb2tZZ2VWTTBJcGFCLWE4YjVxN0UwdnpoTU1RVHZYbFZfSlpaaERjWGt3dklaekZ4UGRqZHVGWnVab3lnZXJKdXRpNjdtLXF1TlJ5WWZfN0lNeTZCNTgzbXMtZ0tqS2dFb2M2cG54WHo0WFJIM2N3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOWnRfaklFWkdXRm1KWEI5TFJqaVZMR3lGWTBFSGYtdkpaakN1Vm1lZU5NaGg4Zy1PdG0wNEFUcmswMXU5V0U4emRRbkFBdTBoVTRFSXd3VnFZR2xUMVZIdjBmekEtb2lsR3ZxUGM4Wl9QeWppNE9Qb0swT3ZiQk4xYmstdjhTZzB0X3c?oc=5", "source_name": "Market source", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for PMV Pharmaceuticals (PMVP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBoZlUxLTNGYnVqVWdzbU5ocW1wWTFMc0VKMXptdlM0dmR0dDhhMnRoV0ZIWDFwWVg0bFQ3Z2JJV3JjU082VmEyYWU1X1k5amRIM3FlY3pvYk12U1hod2VnUHQtcC1tal83MmdZbFh1S3J0bWZZbU01ZA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-12-06T10:55:06+00:00", "published_display": "06 Dec 2022 10:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pmv Pharmaceuticals Stock Price Forecast. Should You Buy PMVP?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTFBNRFI1NEc4VDFHWWJleHhBVklBUzdRcGhDVlVUN25rQ1lpcEk2TG9PWTJ0b2J5NFhDUUFYZFJwdS1uQnd1dm1UdQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-04T02:51:29+00:00", "published_display": "04 Dec 2020 02:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMVP Stock Price and Chart \u2014 NASDAQ:PMVP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9NbTlzakkxT2xSWm5CQTMtci1ubEpPUW9VSGNCTWFjaUV5Y19mUjFZR1Q4WDZ0cGFsNG1VRlFhSnV6VXJ1X0RibHZwcWJFSzhIYW90QjVEUHdEM3VN?oc=5", "source_name": "TradingView", "published_at": "2020-09-25T07:00:00+00:00", "published_display": "25 Sep 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ArrowMark Colorado Holdings (PMVP) holds 3.67% stake in PMV Pharmaceuticals", "summary": "ArrowMark Colorado Holdings, LLC has reported a 3.67% beneficial ownership stake in PMV Pharmaceuticals, Inc., totaling 1,959,579 shares of common stock as of June 30, 2026. This filing, an amendment to Schedule 13G, indicates ArrowMark holds sole voting and dispositive power ove", "url": "https://www.stocktitan.net/sec-filings/PMVP/schedule-13g-a-pmv-pharmaceuticals-inc-amended-passive-investment-dis-ceb6fa3c125f.html", "source_name": "Stock Titan", "published_at": "2026-07-10T15:41:00", "published_display": "10 Jul 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Coverage Assumed by Ladenburg Thalmann at Buy", "summary": "Ladenburg Thalmann has initiated coverage on PMV Pharmaceuticals (NASDAQ:PMVP) stock with a \"Buy\" rating. The firm has set a new price target of $17.00 for the biopharmaceutical company, indicating confidence in its future performance.", "url": "https://www.moomoo.com/news/post/72660637/pmv-pharmaceuticals-coverage-assumed-by-ladenburg-thalmann-at-buy", "source_name": "Moomoo", "published_at": "2026-07-09T08:40:55", "published_display": "09 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Price Target Announced at $3.00/Share by Ladenburg Thalmann", "summary": "Ladenburg Thalmann has set a price target of $3.00 per share for PMV Pharmaceuticals (NASDAQ:PMVP). This announcement reflects an analyst's valuation of the company's stock, providing investors with a benchmark for potential future performance.", "url": "https://www.moomoo.com/news/post/72660635/pmv-pharmaceuticals-price-target-announced-at-3-00-share-by", "source_name": "Moomoo", "published_at": "2026-07-08T20:39:21", "published_display": "08 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals outlines its cancer drug pipeline as shares trade quietly", "summary": "PMV Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on precision oncology by targeting the p53 pathway in cancer. The company's pipeline revolves around developing therapies that modulate this key tumor suppressor mechanism, positioning it within the precisio", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pmv-pharmaceuticals-outlines-its-cancer-drug-pipeline-as-shares-trade/69715181", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:10:45", "published_display": "07 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals holds the focus as investors await the next catalyst.", "summary": "PMV Pharmaceuticals, an oncology company focused on p53 mutations, is attracting investor attention, with its stock performance heavily reliant on its clinical pipeline, financing, and trial readouts rather than a single event. The company's lead candidate, PMV-02, targets specif", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pmv-pharmaceuticals-holds-the-focus-as-investors-await-the-next-catalyst/69682268", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T18:40:24", "published_display": "03 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article provides the \"Price to earnings forward\" value for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP). It's a quick data point for the company's financial overview, indicating a specific period, value, and change metrics. The article is hosted on TradingView, a financial chart", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:10:40", "published_display": "28 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article displays the forward price-to-sales ratio for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP). It is a financial data point presented by TradingView, indicating the company's valuation based on its future sales. The page also lists associated market data providers and copyri", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:24", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PMVP)", "summary": "This article provides an overview of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) stock performance, financial actuals, and analyst estimates. It details the current stock price, market capitalization, earnings, and revenue, alongside historical highs and lows. The piece also includes", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T03:10:08", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article focuses on the \"Price to book forward\" financial metric for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP). It appears to be a stub or a section within a larger financial data platform, providing a snapshot of this specific financial ratio without additional commentary or ", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:47", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article provides the enterprise value to EBITDA forward for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP). It specifies that the market is currently closed with no trades, and the content is primarily a data point presented within the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T07:41:04", "published_display": "25 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPOWprcm5KLVoyMFdmWlRsRmdpVG1aX1JOTUEyVG9xekVVSVJhNTZ5ME1UUVB6ZnlSTzZSRmZ3SU1DU2syRlhPQXlRVG1xRnZaR0RqZ2pYd3hBT29PRXN0bGk1M1BuSVBEZ0IzZ2VDY1lUakJtQ1RRWkY4a0tKbFJQMFEyakRqVnNFLUF0V1Y4REh4dExxdFYtWnY2TmRBZVJ6YnNtNA?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Institutional Confidence", "summary": "This article provides details on the institutional confidence in PMV Pharmaceuticals Inc (PMVP), as reflected by institutional shareholding data. It lists key institutional shareholders, their shareholdings, and changes in their positions. The data indicates varying levels of act", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T23:39:17", "published_display": "18 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for PMV Pharmaceuticals Inc (PMVP), including EPS and revenue growth estimates. Based on 5 analysts, the stock has a \"Buy\" rating with an average target price of $6.00, representing a significant upside. The article also details recent a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:39", "published_display": "18 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for PMV Pharmaceuticals Inc (PMVP), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these metrics have not yet been disclosed by the company. The article also includes current stock perfo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:39", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of PMV Pharmaceuticals Inc (PMVP), detailing its current stock price, market cap, and a breakdown of various technical indicators and moving averages. The analysis includes a summary of buy and sell signals based on MACD, RSI, KDJ, and o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/technical", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:39", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a detailed financial overview of PMV Pharmaceuticals Inc (PMVP). It highlights that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The article includes current stock pricing, market c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:48", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Inc (PMVP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of PMV Pharmaceuticals Inc (PMVP) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years and shows no historical data for stock splits. The current stock price a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmvp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:47", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMVP SEC Filings - Pmv Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Pmv Pharmaceuticals (PMVP) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details recent filings such as an 8-K report from August 2025 and several Form 4 insider transaction disclosures from July 2025, which i", "url": "https://www.stocktitan.net/sec-filings/PMVP/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-14T23:40:49", "published_display": "14 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Stock (US7301281085): Quiet session puts fundamentals and balance sheet in focus", "summary": "PMV Pharmaceuticals (PMVP) is experiencing a quiet trading session, bringing focus to its fundamentals, clinical pipeline, and cash position. As a clinical-stage oncology company, its valuation is currently based on its lead p53-targeted program, discovery platform, and balance s", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pmv-pharmaceuticals-stock-us7301281085-quiet-session-puts-fundamentals/69528818", "source_name": "AD HOC NEWS", "published_at": "2026-06-12T15:39:06", "published_display": "12 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) Q1 2026 Earnings: EPS Beat Driven by Tight Cost Control, Stock Slips on Lack of Revenue - Free Cash Flow Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNZ0xxM3JBb090SlRYRGZldnhkNWpuTjIweUJ0OUxxdUg1bXE5Wm9fVXZ3T1BROUtIdm80dDR5OUtKSWNUVUhSeXhaUTVNdExCREFDRnIxby1mcld1elZ1YWx1S3FEZ0h3aUlnOEUtREx1TkNVQ0pnZVptUmRLcGRYYlp2U1VHcmdhMHprR2hSVzBqQkxXWHVKblVkUFpXNUxkOExsT0VSMzVIbTM0RkxBVkZsbVFmT3VBZW5MekhwalNKLWZ2WEVMQm1sVnFncGhxcXJFTWpDYUZIM21VM1BhVS1rVGF3Zw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "PMV Pharmaceuticals (PMVP) has dropped 26.1% in the past four weeks but may be poised for a trend reversal due to its oversold status, indicated by an RSI of 27.99. Additionally, Wall Street analysts have significantly raised their earnings estimates for the company, and PMVP hol", "url": "https://finance.yahoo.com/markets/stocks/articles/pmv-pharmaceuticals-pmvp-loses-26-133502096.html", "source_name": "Market source", "published_at": "2026-06-10T09:35:00", "published_display": "10 Jun 2026 09:35", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) director receives 42,000 stock options at $1.1900", "summary": "PMV Pharmaceuticals director Arnold J. Levine was granted 42,000 stock options at an exercise price of $1.1900 per share, as reported in a Form 4 SEC filing. These options are set to expire on June 4, 2036, and will vest on the earlier of June 4, 2027, or the company's next annua", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-445e8f3bf3fd.html", "source_name": "Stock Titan", "published_at": "2026-06-06T08:10:56", "published_display": "06 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) director awarded 42,000 stock options at $1.19", "summary": "PMV Pharmaceuticals director Kirsten Flowers was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. These options will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting. This insider transaction in", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-7f57522338d4.html", "source_name": "Stock Titan", "published_at": "2026-06-06T06:10:40", "published_display": "06 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) director gifts 84K stock options to trust", "summary": "PMV Pharmaceuticals director Carol Giltner Gallagher recently reported that she received a stock option grant for 42,000 shares and transferred options covering a total of 84,000 shares as bona fide gifts, primarily to The Gallagher Revocable Trust. These transactions were non-ma", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-63219f14b852.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:40:11", "published_display": "05 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals (PMVP) grants director 42,000 options at $1.19", "summary": "PMV Pharmaceuticals director Laurie Stelzer was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. These options will vest on the earlier of June 4, 2027, or the date of the company's next annual stockholder meeting. This transaction", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-5f492428899e.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:40:11", "published_display": "05 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at PMV Pharmaceuticals (PMVP) granted 42,000 options at $1.19", "summary": "PMV Pharmaceuticals director Charles M. Baum was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. The options will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting. Following this transaction, M", "url": "https://www.stocktitan.net/sec-filings/PMVP/form-4-pmv-pharmaceuticals-inc-insider-trading-activity-a5b14a55b13f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:40:11", "published_display": "05 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results", "summary": "PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) announced the results of its 2026 Annual Meeting of Stockholders held virtually on June 4, 2026. Key outcomes included the election of two Class III Directors, David H. Mack, Ph.D. and Laurie Stelzer, and a non-binding advisory approval of", "url": "https://www.minichart.com.sg/2026/06/05/pmv-pharmaceuticals-inc-files-form-8-k-with-sec-detailing-company-information-and-annual-meeting-results/", "source_name": "Minichart", "published_at": "2026-06-05T14:04:11", "published_display": "05 Jun 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders back PMV Pharmaceuticals (NASDAQ: PMVP) board, pay plans", "summary": "PMV Pharmaceuticals (NASDAQ: PMVP) shareholders at their 2026 annual meeting elected David H. Mack, Ph.D. and Laurie Stelzer as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation for named executive of", "url": "https://www.stocktitan.net/sec-filings/PMVP/8-k-pmv-pharmaceuticals-inc-reports-material-event-0adc52b9e1a2.html", "source_name": "Stock Titan", "published_at": "2026-06-05T12:39:39", "published_display": "05 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity", "summary": "PMV Pharmaceuticals, Inc. (PMVP) shows positive clinical trial activity for rezatapopt in cancer treatment, prompting Oppenheimer to maintain an Outperform rating despite a reduced price target. Although the company has sufficient cash for operations through Q1 2027 for NDA submi", "url": "https://www.insidermonkey.com/blog/why-pmv-pharmaceuticals-inc-pmvp-faces-funding-concerns-despite-positive-trial-activity-1773525/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-02T16:10:50", "published_display": "02 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Popular Penny Stocks on Robinhood to Watch in 2026", "summary": "PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is highlighted as a popular penny stock on Robinhood. Oppenheimer recently reduced its price target on PMVP to $5, maintaining an Outperform rating, recognizing encouraging clinical activity for rezatapopt in cancer treatment. The company ", "url": "https://www.insidermonkey.com/blog/5-popular-penny-stocks-on-robinhood-to-watch-in-2026-1771177/4/", "source_name": "Insider Monkey", "published_at": "2026-05-31T15:09:34", "published_display": "31 May 2026 15:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals, Inc. - Common Stock (Nasdaq:PMVP) Stock Quote", "summary": "This page provides a stock quote and detailed financial information for PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), including its current price, trading volume, and 52-week range. It also features a feed of recent news and performance data for the company, highlighting drug develop", "url": "https://markets.financialcontent.com/stocks/quote?Symbol=537%3A2578286838&Language=Spanish", "source_name": "FinancialContent", "published_at": "2026-05-16T09:39:48", "published_display": "16 May 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of PMV Pharmaceuticals, Inc. \u2013 NASDAQ:PMVP", "summary": "This article provides details on the number of shareholders for PMV Pharmaceuticals, Inc. (NASDAQ: PMVP). It is a financial data page from TradingView, explicitly stating the company's ticker and market. The content primarily focuses on presenting shareholder data with period, va", "url": "https://www.tradingview.com/symbols/NASDAQ-PMVP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-15T20:40:41", "published_display": "15 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pmv-pharmaceuticals-reports-first-quarter-120000541.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T12:00:00+00:00", "published_display": "12 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Announces Board Chair Transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOR0x5SlhfR3hCcEt5Z1NfTnV3SlpoaG9mMzdCankzMlNZWDc2cExPYkstV0RweXpYWHh1STBGZUlndDlad2dfOThGRkVKeWRRRXRidzNuWTdtMk9sZ1hON1ZJd2l4QnhHNEF6XzRCdDBhXzJDbEtSMmpGdERDQUtqWlh5bDlNYUVTZ2NVQlJzM1Y1RDRmZS1ZQVNscjFFdUpZSVVoSmpVd2hEb0xiekVQVkxTUkpILTAzSlRwS0w3SXBOQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRWMteFZsN3R3dUY4eXpDTThkMlV2YzFwclF2bVRjTEdIbV9EQ013YV9PLWtaS2ZQTWxDbXJ2N2FEanhhZkVHZEIwWGh2dk9YOUt4NGp6OGEzSnN1c2ZLUlV2UUJORVdSaFY4b0VIb2RFNTZJMV9rQmtuNVN1cUZVOHdtdnBPcHNJRWMtelc2MVZfUV9DQWx1NmNWSVlMOGx5ZkNB?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxPY2s0eEdaaE9FMlhpOFFiM0RSd25zVF80Y096RnBXTlZvVU0wbG03Y1dXV3ppZVpjcW1KU3hfUFZGLU1DM3MxQ2htSFdPZy01SGpBdUxDSF9ka09tRktLdVVuNUxyT0F3c3B5MnBOQjlnbnp0M0dEd29zNi1NSTUxb2tZZ2VWTTBJcGFCLWE4YjVxN0UwdnpoTU1RVHZYbFZfSlpaaERjWGt3dklaekZ4UGRqZHVGWnVab3lnZXJKdXRpNjdtLXF1TlJ5WWZfN0lNeTZCNTgzbXMtZ0tqS2dFb2M2cG54WHo0WFJIM2N3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOWnRfaklFWkdXRm1KWEI5TFJqaVZMR3lGWTBFSGYtdkpaakN1Vm1lZU5NaGg4Zy1PdG0wNEFUcmswMXU5V0U4emRRbkFBdTBoVTRFSXd3VnFZR2xUMVZIdjBmekEtb2lsR3ZxUGM4Wl9QeWppNE9Qb0swT3ZiQk4xYmstdjhTZzB0X3c?oc=5", "source_name": "Market source", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for PMV Pharmaceuticals (PMVP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBoZlUxLTNGYnVqVWdzbU5ocW1wWTFMc0VKMXptdlM0dmR0dDhhMnRoV0ZIWDFwWVg0bFQ3Z2JJV3JjU082VmEyYWU1X1k5amRIM3FlY3pvYk12U1hod2VnUHQtcC1tal83MmdZbFh1S3J0bWZZbU01ZA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-12-06T10:55:06+00:00", "published_display": "06 Dec 2022 10:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pmv Pharmaceuticals Stock Price Forecast. Should You Buy PMVP?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTFBNRFI1NEc4VDFHWWJleHhBVklBUzdRcGhDVlVUN25rQ1lpcEk2TG9PWTJ0b2J5NFhDUUFYZFJwdS1uQnd1dm1UdQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-04T02:51:29+00:00", "published_display": "04 Dec 2020 02:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMVP Stock Price and Chart \u2014 NASDAQ:PMVP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9NbTlzakkxT2xSWm5CQTMtci1ubEpPUW9VSGNCTWFjaUV5Y19mUjFZR1Q4WDZ0cGFsNG1VRlFhSnV6VXJ1X0RibHZwcWJFSzhIYW90QjVEUHdEM3VN?oc=5", "source_name": "TradingView", "published_at": "2020-09-25T07:00:00+00:00", "published_display": "25 Sep 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 48, "sentiment_summary": {"positive": 11, "negative": 2, "neutral": 35, "score": 54, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.55, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 1.24, "latest_week": "2026-07-10", "one_week_move": 1.6, "four_week_move": 11.7, "twelve_week_move": -10.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.738046, "market_dynamics_buy_signal": false, "relative_strength": -19.898262, "fair_value_gap": -35.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.4573, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.6% over one week, +11.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 6}, {"label": "GlobeNewswire", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "AD HOC NEWS", "count": 2}, {"label": "Insider Monkey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 5}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.6% over one week, +11.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ArrowMark Colorado Holdings (PMVP) holds 3.67% stake in PMV Pharmaceuticals"}], "updated_at": "2026-07-16T08:08:07.833494+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}